Spots Global Cancer Trial Database for Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma
Official Title: A Phase II Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma
Study ID: NCT00061672
Interventions
Study Description
Brief Summary: The primary objective of this study is to assess the safety and effectiveness of ABT-510 in subjects with refractory lymphoma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hematology Oncology Associates, Phoenix, Arizona, United States
Arizona Clinical Research Center, Tucson, Arizona, United States
USC - Norris Cancer Center, Los Angeles, California, United States
The Center for Hematology-Oncology, Boca Raton, Florida, United States
Oncology-Hematology Group of South Florida, Miami, Florida, United States
Cancer Centers of Florida, P.A., Orlando, Florida, United States
Kansas City Oncology and Hematology Group, Kansas City, Missouri, United States
Arch Medical Services, INC., St. Louis, Missouri, United States
Albany Regional Cancer Center, Albany, New York, United States
Raleigh Hematology Oncology Clinic, Cary, North Carolina, United States
The West Cancer Clinic, Memphis, Tennessee, United States
MD Anderson Cancer Center, Houston, Texas, United States
Hematology Oncology Associates, San Antonio, Texas, United States
U of W - Comprehensive Care Center, Madison, Wisconsin, United States
Contact Details
Name: Rod Humerickhouse, MD
Affiliation: Abbott
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
